Date: 2016-05-18
Type of information: Presentation of results at a congress
phase: 1a
Announcement: presentation of results at the American Thoracic Society (ATS) 2016 International Conference in San Francisco
Company: Xencor (USA - CA)
Product: XmAb®7195
Action
mechanism: monoclonal antibody. XmAb®7195 is a monoclonal antibody that targets IgE with its variable domain and uses Xencor's XmAb® Immune Inhibitor Fc domain to target FcgammaRIIb, resulting in three distinct mechanisms of action for reducing IgE levels for the potential treatment of allergic disease.
FcgammaRIIb (IIb), also called CD32b, is a receptor for Fc domains on B cells and other immune cells. When engaged, the IIb receptor blocks immune activation pathways and traffics bound soluble antigens out of circulation. Xencor has discovered a series of Fc domain variants with up to a 400-fold increase in binding affinity to FcgammaRIIb derived from just two amino acid changes. These XmAb® Immune Inhibitor Fc domains greatly heighten the properties of IIb receptor engagement and have potential as building blocks for drug candidates in autoimmune, allergic and inflammatory diseases.
Disease:
Therapeutic area: Allergic diseases - Inflammatory diseases - Respiratory diseases
Country: USA
Trial
details: The Phase 1a study was a randomized, double-blind, placebo-controlled, ascending dose trial conducted in three parts. In Part 1, 40 healthy subjects were randomized to receive a single IV administration of XmAb®7195 or matching placebo (6:2) in five consecutive dose cohorts of eight subjects each. In Part 2, 16 otherwise healthy subjects with a history of allergic rhinitis and/or allergic conjunctivitis and/or atopic dermatitis with elevated serum IgE ( > 300 IU/mL) were randomized to receive a single IV administration of XmAb7195 or matching placebo (6:2) in two consecutive dose cohorts of eight subjects each. In Part 3, 16 healthy subjects were randomized to receive two sequential IV administrations (Day 1 priming dose of 0.3 mg/kg and Day 8 second ascending dose) of XmAb7195 or matching placebo (6:2) in two consecutive dose cohorts of eight subjects each. The primary and secondary objectives of the study were to determine the safety and tolerability profile of IV administration of XmAb7195 and to characterize the pharmacokinetics (PK) and immunogenicity of IV administration of XmAb7195, respectively. Exploratory objectives include the determination of the effect of XmAb7195 on serum free and total IgE and the effect on basophil surface IgE and basophil Fc?RI expression levels. (NCT02148744)
Latest
news: * On May 18, 2016, Xencor announced that it presented complete data results from a Phase 1a, first-in-human study for XmAb®7195. XmAb7195 was generally well tolerated with transient, asymptomatic thrombocytopenia reported at doses ?2.0 mg/kg, and induced rapid and extensive depletion of serum IgE at all doses tested, including in high IgE subjects. Results of this study support further development in a multiple ascending dose study with subcutaneous administration, expected to begin in 2016. The poster has been presented at the American Thoracic Society (ATS) 2016 International Conference in San Francisco. The data showed rapid reduction in circulating free IgE levels to below the limit of detection ( < 9.59 ng/mL) for 93% of XmAb7195 treated healthy adult subjects in Part 1 that had detectable free IgE pre-dose, including those at the lowest dose evaluated of 0.3 mg/kg, with total IgE reduced in a parallel fashion. Five of six high IgE subjects dosed at 0.6 mg/kg XmAb7195 and nine of 12 subjects across all doses had sustained undetectable free IgE following infusion, with a median pre-dose free IgE of 710 ng/mL (424 - 1777 ng/mL). High IgE subjects treated with XmAb7195 single infusions across all dose levels had profound (mean pre-dose 583.5 IU/mL, mean nadir 7.77 IU/mL) reductions of total IgE, which were sustained for at least a week at ?1.0 mg/kg doses. Total IgE reduction differentiates XmAb7195 from other anti-IgE therapeutic antibodies, which actually increase total IgE levels. Because total IgE assays, unlike free IgE assays, are readily available to clinicians, the effect of XmAb7195 on total IgE levels could enable for the first time simple monitoring, and potentially adjustment, of anti-IgE therapy. The adverse event of thrombocytopenia, which was transient and asymptomatic, was reported in seven out of seven subjects treated with ?2 mg/kg doses of XmAb7195, and in no subjects treated with < 2 mg/kg. The nadir in platelet count occurred by 24 hours post-infusion and recovery began by 48 hours, with near full recovery by Day 8 in most subjects, at which time serum drug concentrations still exceeded levels that eliminate detectable IgE. Dose-dependent, non-clinically significant, reductions in platelet count were observed in most subjects that received ?0.75 mg/kg XmAb7195. In Part 3 of the study, decreases in platelet count were seen after the second dose on Day 8 for the 1.0 mg/kg dose level, even for subjects with no detectable free IgE after the Day 1 0.3 mg/kg priming dose, but not seen after the second dose for the 0.3 mg/kg dose level. There was no apparent relationship of thrombocytopenia to known polymorphisms of Fcg receptor IIa. No evidence of thrombocytopenia has been observed in any of the clinical trials of XmAb5871, an anti-CD19 antibody with the identical XmAb Immune Inhibitor Fc domain as that of XmAb7195. Moderate urticaria was reported in a total of 10 of 54 XmAb7195 treated subjects with an apparent correlation of dose with frequency of occurrence. In all cases regardless of dose, the signs/symptoms of urticaria were mild, non-diffuse and easily treated with oral antihistamine, and the study drug infusions were continued to completion without worsening of symptoms. Importantly, two subjects that experienced urticaria during the first dose in Part 3 did not have recurrence during or after the second dose. The average half-life of XmAb7195 in healthy subjects across the dose levels of 0.3 to 3.0 mg/kg was 3.9 days, with little, if any, dependence on dose level. Only 1 of 54 (1.9%) XmAb7195 treated subjects was observed to have a confirmed positive anti-drug antibody result.
